Evidence map›Paper›PMID 36683076›Full record

ArticleEuropean journal of hybrid imaging2023

Irina Vierasu, Gaetan Van Simaeys, Nicola Trotta, Simon Lacroix, Guy Bormans, Simone Albisinni, Thierry Quackels, Thierry Roumeguère, Serge Goldman

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in European journal of hybrid imaging, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.3field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Irina VierasuNuclear Medicine Department & PET/Biomedical Cyclotron Unit, Hôpital Erasme, Université libre de Bruxelles (ULB), Route de Lennik 808, 1070, Brussels, Belgium. Ortansa-Irina.Vierasu@erasme.ulb.ac.be.ORCID http://orcid.org/0000-0002-0640-0916
Gaetan Van SimaeysNuclear Medicine Department & PET/Biomedical Cyclotron Unit, Hôpital Erasme, Université libre de Bruxelles (ULB), Route de Lennik 808, 1070, Brussels, Belgium.
Nicola TrottaNuclear Medicine Department & PET/Biomedical Cyclotron Unit, Hôpital Erasme, Université libre de Bruxelles (ULB), Route de Lennik 808, 1070, Brussels, Belgium.
Simon LacroixNuclear Medicine Department & PET/Biomedical Cyclotron Unit, Hôpital Erasme, Université libre de Bruxelles (ULB), Route de Lennik 808, 1070, Brussels, Belgium.
Guy BormansRadiopharmaceutical Recherche, KU Leuven, Leuven, Belgium.
Simone AlbisinniUrology Department, Cliniques Universitaires de Bruxelles, HUB, Hôpital Erasme, Université libre de Bruxelles (ULB), Brussels, Belgium.
Thierry QuackelsUrology Department, Cliniques Universitaires de Bruxelles, HUB, Hôpital Erasme, Université libre de Bruxelles (ULB), Brussels, Belgium.
Thierry Roumeguère *Urology Department, Cliniques Universitaires de Bruxelles, HUB, Hôpital Erasme, Université libre de Bruxelles (ULB), Brussels, Belgium.
Serge Goldman *Nuclear Medicine Department & PET/Biomedical Cyclotron Unit, Hôpital Erasme, Université libre de Bruxelles (ULB), Route de Lennik 808, 1070, Brussels, Belgium.
Université Libre de Bruxelles · BEKU Leuven · BE

Funding

Walloon region 7559 Prospect
6 · The paper itself

Abstract

backgroundPositron emission tomography/computed tomography (PET/CT) using radiotracers that bind to the prostate-specific membrane antigen (PSMA) is mainly used in biochemical recurring prostate cancer. The aim of our study was to assess the usefulness of

methodsWe enrolled a total of 10 patients with intermediate- and high-risk PCa diagnosed by multiparametric-MRI followed by systematic and targeted biopsies, eligible for radical prostatectomy with extended lymph node dissection. Clinical team was blind to the results of the pre-surgery

resultsAll pre-surgery

conclusionThis pilot study indicates that pre-surgery

Indexed as

High-risk prostate cancerInitial stagingIntermediate-risk prostate cancerPost-surgery 18F-JK-PSMA7 PET/CTPre-surgery 18F-JK-PSMA7 PET/CT

Identifiers

PMID36683076
PMCPMC9868215
OpenAlexW4317712962

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.